Related Experiment Video
Updated: Jul 11, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Inhaled corticosteroids in chronic obstructive pulmonary disease
Samy Suissa1, Ryan McGhan, Dennis Niewoehner
1Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Canada.
Proceedings of the American Thoracic Society
|September 20, 2007
Summary
The effectiveness of inhaled corticosteroids (ICS) for chronic obstructive pulmonary disease (COPD) is debated. While some studies show minor benefits, rigorous trials reveal significant uncertainty about ICS efficacy in COPD patients.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- The role of inhaled corticosteroids (ICS) in managing chronic obstructive pulmonary disease (COPD) is a subject of ongoing debate.
- Existing research, including randomized controlled trials (RCTs) and observational studies, has yielded conflicting results regarding ICS effectiveness.
Purpose of the Study:
- To critically evaluate the evidence on the effectiveness of inhaled corticosteroids in patients with chronic obstructive pulmonary disease.
- To address the controversies and uncertainties surrounding ICS use in COPD management.
Main Methods:
- Review of randomized controlled trials, meta-analyses, medication withdrawal studies, and observational reports.
- Analysis of study designs, statistical methods, and potential biases, such as immortal time bias in observational studies.
- Examination of findings from major RCTs like TORCH and Optimal.
Main Results:
- Observational studies suggest benefits but are criticized for methodological flaws like immortal time bias.
- Some RCTs indicate modest improvements in lung function, health status, and reduced exacerbations and mortality, but face criticism regarding follow-up and statistical analysis.
- Recent rigorous trials (TORCH, Optimal) found no benefit for the primary outcome with ICS and long-acting beta-agonist combination therapy.
Conclusions:
- Significant uncertainty persists regarding the overall benefits of ICS in COPD patients.
- Future RCTs employing rigorous methodology are necessary to definitively ascertain the role of ICS in COPD treatment.
- The combination of ICS with long-acting beta-agonists shows potential but requires further validation through robust trials.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...